Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
NCT01004978
Completed
This randomized phase III trial studies chemoembolization and sorafenib tosylate to see how well they work compared with chemoembolization alone in treating patients with liver cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as doxorubicin hydrochloride, mitomycin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Chemoembolization kills tumor cells b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2023
Locations: Saint Joseph Medical Center, Bloomington, Illinois +54 locations
Conditions: Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Register for Updates
A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
NCT03684811
Completed
This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent and in combination with other anti-cancer drugs in patients with advanced solid tumors and gliomas. The study is divided into two parts: single agent FT-2102 followed by combination therapy. Part 1: A single agent, open-label study in up to five cohorts (glioma, hepatobiliary tumors, chondrosarcoma, intrahepatic cholangiocarcinoma, and other IDH1 mutant solid tumors) that will include a Phase 1 dos... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/16/2023
Locations: Northwestern University, Lurie Comprehensive Cancer Center, Chicago, Illinois
Conditions: Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas), Cohort 3a and 3b: Chondrosarcoma, Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma, Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations
Register for Updates
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
NCT00942331
Completed
This randomized phase III trial studies gemcitabine hydrochloride, cisplatin, and bevacizumab to see how well they work compared with gemcitabine hydrochloride and cisplatin in treating patients with urinary tract cancer that has spread to other places in the body. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Im... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/12/2023
Locations: Saint Anthony's Health, Alton, Illinois +69 locations
Conditions: Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Prostate Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma AJCC v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Pelvis Cancer AJCC v7, Stage IV Ureter Cancer AJCC v7, Stage IV Urethral Cancer AJCC v7, Unresectable Urothelial Carcinoma
Register for Updates
Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
NCT02709512
Completed
This is a study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme versus placebo in patients with malignant pleural mesothelioma. Malignant pleural mesothelioma have been found to require arginine, an amino acid. Thus the hypothesis is that by restricting arginine with ADI-PEG 20, the malignant pleural mesothelioma cells will starve and die.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/09/2023
Locations: University of Chicago, Chicago, Illinois
Conditions: Mesothelioma
Register for Updates
A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy
NCT02864251
Completed
The main purpose of this study is to determine whether nivolumab + chemotherapy is effective as compared to chemotherapy in the treatment of patients with EGFR mutation, NSCLC who failed first line (1L) or second-line (2L) EGFR TKI therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/06/2023
Locations: Local Institution - 0004, Chicago, Illinois
Conditions: Non-Small-Cell Lung Carcinoma
Register for Updates
Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT02741570
Completed
The main purpose of this study is to compare nivolumab and ipilimumab with the extreme regimen as first line treatment in patients with recurrent or metastatic squamous cell of the head and neck cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/31/2023
Locations: Local Institution - 0006, Chicago, Illinois
Conditions: Head and Neck Cancer
Register for Updates
PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer
NCT04099888
Terminated
This study will assess the safety and effectiveness of fimaporfin-induced photochemical internalisation (PCI) of gemcitabine complemented by systemic gemcitabine/cisplatin chemotherapy compared to gemcitabine/cisplatin alone, in patients with inoperable cholangiocarcinoma (CCA). Participants will be randomly assigned to one of the treatment groups and will receive study treatment for 6 months, followed by assessments every 3 months, as applicable.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2023
Locations: University of Chicago Medical Center, 5841 South Maryland Avenue, Chicago, Illinois
Conditions: Cholangiocarcinoma
Register for Updates
Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
NCT00078949
Completed
RATIONALE: Drugs used in chemotherapy, such as dexamethasone, cisplatin, gemcitabine, and cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal... Read More
Gender:
ALL
Ages:
Between 16 years and 65 years
Trial Updated:
08/03/2023
Locations: Rush-Presbyterian-St. Luke's Medical Centre, Chicago, Illinois
Conditions: Lymphoma
Register for Updates
Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer
NCT00047008
Completed
RATIONALE: Radiation therapy (RT) uses high-energy x-rays to damage tumor cells. Giving radiation therapy in different ways and combining it with chemotherapy before surgery may kill more tumor cells. It is not yet known which radiation therapy regimen combined with chemotherapy with or without surgery is more effective for head and neck cancer. PURPOSE: Randomized phase III trial to compare two different radiation therapy regimens combined with cisplatin with or without surgery in treating pat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2023
Locations: Northwest Community Hospital, Arlington Heights, Illinois +6 locations
Conditions: Head and Neck Cancer
Register for Updates
Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach
NCT00003237
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug, and giving them after surgery, may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, consisting of paclitaxel and cisplatin, given after surgery in treating patients with cancer of the esophagus or stomach.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/21/2023
Locations: Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois +5 locations
Conditions: Esophageal Cancer, Gastric Cancer
Register for Updates
Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer
NCT00003298
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy, radiation therapy, and surgery may kill more tumor cells. E7296 was conducted to study neoadjuvant chemotherapy and postoperative chemoradiation therapy in patients diagnosed with high-risk gastric cancer using a new neoadjuvant regimen: paclitaxel plus cisplatin. It was hypothesized that t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois +3 locations
Conditions: Gastric Cancer
Register for Updates
Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer
NCT00003309
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug and combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by radiation therapy in treating adult patients with brain cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/20/2023
Locations: Veterans Affairs Medical Center - Lakeside Chicago, Chicago, Illinois +2 locations
Conditions: Brain and Central Nervous System Tumors
Register for Updates